Lineage Cell Therapeutics

DelveInsight's 'Spinal Cord Injury Pipeline Insight, 2024' report details 35+ therapies in development by 35+ companies, including Athersys, Olatec Therapeutics, and AbbVie, focusing on mechanism of action, clinical trials, and market prospects. Key therapies include Allogeneic stem cell therapy, OLT1177, and Elezanumab, with ongoing trials and potential market impact. The report covers pre-clinical to marketed phases, regulatory approvals, and market dynamics.

Lineage Cell Therapeutics to report Q3 2024 financial results and provide business update on Nov 14, 2024, hosting a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT.

Katherine Talcott, MD, discusses potential therapies for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at OSN New York 2024, highlighting ANX007, Danicopan ALXN 2040, AVD-104, JNJ-1887, ASP7317, RG6501, elamipretide, Glideuretinal, AREDS/AREDS2, and ONL1204. ANX007 showed significant protection from vision loss in the ARCHER Trial, while Danicopan ALXN 2040 is an oral agent inhibiting complement factor D. AVD-104 demonstrated visual acuity gains in the SIGLEC study. Gene therapies like JNJ-1887 and ASP7317 aim to protect retinal cells. Elamipretide showed positive effects on visual function in the ReCLAIM study. Glideuretinal and AREDS/AREDS2 are antioxidants, and ONL1204 is a Fas inhibitor reducing retinal cell apoptosis.

Lineage Cell Therapeutics (LCTX) to present at Maxim Group 2024 Virtual Healthcare Summit on Oct 15, 2024, at 11:00 a.m. ET. CEO Brian M. Culley will discuss the company's allogeneic cell therapies in a fireside chat hosted by Jason McCarthy, Ph.D.